Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Non-Hodgkin B-cell Lymphoma

Next Previous
Trial Profile

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Non-Hodgkin B-cell Lymphoma

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunvozertinib (Primary)
  • Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms WU-KONG3
  • Sponsors Dizal Pharmaceutical

Most Recent Events

  • 25 Feb 2025 Status changed from suspended to withdrawn prior to enrolment.
  • 04 Aug 2022 According to a Dizal Pharmaceutical media release, data from this trial will be presented at 2022 World Conference on Lung Cancer (WCLC).
  • 10 Jun 2021 Planned initiation date changed from 1 Sep 2020 to 1 Aug 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top